VTGN logo

VistaGen Therapeutics (VTGN) Company Overview

Profile

Full Name:

Vistagen Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 21, 2011

Indexes:

Not included

Website:

http://www.vistagen.com

Description:

VistaGen Therapeutics is a biotechnology company focused on developing new treatments for mental health disorders. They use innovative technology to create drugs that aim to improve the lives of patients with conditions like depression and anxiety. Their goal is to provide safer and more effective therapies.

Key Details

Price

$2.55

Market Cap

$73.60 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$1.06 M(+568.72% YoY)

Annual EPS

-$1.52(+82.14% YoY)

PE Ratio

-

Annual ROE

-46.47%

Annual Debt To Equity

0.00

Beta

0.82

Events Calendar

Earnings

Next earnings date:

Jun 11, 2025

Recent quarterly earnings:

Feb 13, 2025

Recent annual earnings:

Jun 11, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 7, 2023

Analyst ratings

Recent major analysts updates

Dec 7, 23 Jefferies
Buy
Nov 14, 23 Stifel
Buy
Sep 5, 23 Maxim Group
Buy
Aug 7, 23 Maxim Group
Buy
Jul 26, 22 Maxim Group
Hold
Jul 22, 22 William Blair
Market Perform
May 20, 21 Baird
Outperform
Feb 18, 21 Jefferies
Buy
Jan 4, 21 William Blair
Outperform
Oct 8, 20 Aegis Capital
Buy

Screeners with VTGN included

Growing Shares Outstanding
US stocks
Stocks below SMA 200
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$2.55
VTGN price is $2.55

Price All-time High

$1890.00
VTGN price is currently -99.87% below its historical high of $1890.00

Price Analysts Target

$12.00
VTGN price is currently -78.75% lower than the consensus analysts' forecast

Price Most Recent Change

-3.77%
VTGN price was down -3.77% on Mar 6, 2025

Price YTD Change

-14.72%
VTGN price is down -14.72% since January 1st

Price 3-Year Change

-93.09%
VTGN price is down -93.09% over the past 3 years

Market cap

Market Cap

$73.60 M
VTGN market capitalization is $73.60 million

Market Cap 3-Year Change

-71.03%
VTGN market capitalization is down -71.03% over the past 3 years

Market Cap All-time High

$660.66 M
VTGN market capitalization is currently -88.86% below its historical high of $660.66 million

Market Cap Sector Rank

41.32%
VTGN market capitalization is higher than 41.32% of companies in Healthcare sector

Technical

Beta

0.82
VTGN beta is 0.82

200-day SMA

$3.17
VTGN price is currently -19.44% below its 200-day simple moving average

14-day RSI

47.42
VTGN 14-day relative strength index is 47.42

30-day Relative Volume

0.57
VTGN 30-day relative volume is 0.57

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$1.06 M
VTGN annual revenue is $1.06 million

Annual Revenue Analysts Estimate

$657.50 K
VTGN annual revenue is currently +61.83% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

+568.72%
VTGN annual revenue is up +568.72% year-on-year

Annual Revenue Sector Rank

15.37%
VTGN annual revenue is higher than 15.37% of companies in Healthcare sector

Profit

Annual Gross Profit

-
VTGN annual gross profit value is unknown

Annual Gross Margin

-
VTGN annual gross profit margin value is unknown

Annual Operating Profit

-$33.02 M
VTGN annual operating income is -$33.02 million

Annual Operating Margin

-3103.48%
VTGN annual operating profit margin is -3103.48%

Annual Net Income

-$29.36 M
VTGN annual net profit is -$29.36 million

Annual Net Margin

-2759.59%
VTGN annual net profit margin is -2759.59%

EPS

Annual EPS

-$1.52
VTGN annual earnings per share is -$1.52

Annual EPS Analysts Estimate

-$1.74
VTGN annual earnings per share is currently -12.39% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+82.14%
VTGN annual earnings per share is up +82.14% year-on-year

Annual EPS Sector Rank

48.62%
VTGN annual earnings per share is higher than 48.62% of companies in Healthcare sector

ROA & ROE

Annual ROA

-40.57%
VTGN annual return on assets is -40.57%

Annual ROE

-46.47%
VTGN annual return on equity is -46.47%

EBIT & EBITDA

Annual EBIT

-$33.02 M
VTGN annual earnings before interest & taxes is -$33.02 million

Annual EBITDA

-$32.45 M
VTGN annual EBITDA is -$32.45 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
VTGN price to earnings ratio value is unknown

PE Ratio Sector Rank

-
VTGN price to earnings ratio is unknown

PB Ratio

PB Ratio

0.91
VTGN price to book ratio is 0.91

PB Ratio Sector Rank

40.76%
VTGN price to book ratio is higher than 40.76% of companies in Healthcare sector

PS Ratio

PS Ratio

105.44
VTGN price to sales ratio is 105.44

PS Ratio Sector Rank

94.94%
VTGN price to sales ratio is higher than 94.94% of companies in Healthcare sector

Enterprise value

Enterprise Value

$596.36 K
VTGN enterprise value is $596.36 thousand

Enterprise Value Sector Rank

12.28%
VTGN enterprise value is higher than 12.28% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.01
VTGN EV/EBITDA is -0.01

EV/EBITDA Sector Rank

65.05%
VTGN EV/EBITDA is higher than 65.05% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

23.55
VTGN annual current ratio is 23.55

Annual Quick Ratio

-
VTGN annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
VTGN annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
VTGN annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
VTGN piotroski f-score value is unknown

Altman Z-Score

0.93
VTGN altman z-score is 0.93

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$123.65 M
VTGN annual total assets is $123.65 million

Annual Non Current Assets

$2.98 M
VTGN annual long term assets is $2.98 million

Annual Current Assets

$120.67 M
VTGN annual total current assets is $120.67 million

Annual Cash & Cash Equivalents

$119.17 M
VTGN annual cash & cash equivalents is $119.17 million

Equity

Annual Book Value

$114.29 M
VTGN annual book value is $114.29 million

Annual Working Capital

$115.55 M
VTGN annual working capital is $115.55 million

Liabilities

Annual Total Liabilities

$9.37 M
VTGN annual total liabilities is $9.37 million

Annual Total Long Term Liabilities

$4.24 M
VTGN annual total long term liabilities is $4.24 million

Annual Current Liabilities

$5.12 M
VTGN annual total current liabilities is $5.12 million

Annual Accounts Payable

$1.55 M
VTGN annual accounts payable is $1.55 million

Debt

Annual Total Debt

$2.12 M
VTGN annual total debt is $2.12 million

Annual Total Debt 1-Year Change

-21.8%
VTGN annual total debt is down -21.8% year-on-year

Annual Long Term Debt

$1.57 M
VTGN annual long term debt is $1.57 million

Annual Short Term Debt

$550.00 K
VTGN annual short term debt is $550.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$34.09 M
VTGN annual total expenses is $34.09 million

Annual Operating Expenses

$34.09 M
VTGN annual total operating expenses is $34.09 million

Annual Cost Of Goods Sold

-
VTGN annual cost of goods sold value is unknown

Annual SGA

$14.06 M
VTGN annual SGA is $14.06 million

Annual D&A

$568.00 K
VTGN annual depreciation & amortization is $568.00 thousand

Annual Interest Expense

-
VTGN annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$25.81 M
VTGN annual cash flow from operations is -$25.81 million

Annual CFO 1-Year Change

+48.08%
VTGN annual cash flow from operations is up +48.08% year-on-year

Annual CFI

-$61.00 K
VTGN annual cash flow from investing activities is -$61.00 thousand

Annual CFI 1-Year Change

+91.76%
VTGN annual cash flow from investing activities is up +91.76% year-on-year

Annual CFF

$128.40 M
VTGN annual cash flow from financing activities is $128.40 million

Annual CFF 1-Year Change

+12434.49%
VTGN annual cash flow from financing activities is up +12434.49% year-on-year

Free CashFlow

Annual FCF

-$25.87 M
VTGN annual free cash flow is -$25.87 million

Annual FCF 1-Year Change

+48.18%
VTGN annual free cash flow is up +48.18% year-on-year

CAPEX

Annual CAPEX

$61.00 K
VTGN annual capital expenditures is $61.00 thousand

Annual CAPEX 1-Year Change

-71.23%
VTGN annual capital expenditures is down -71.23% year-on-year

Institutional Ownership

Similar stocks

INCR logo
InterCure (INCR)
IMAB logo
I-Mab (IMAB)
ENTX logo
Entera Bio (ENTX)
ARMP logo
Armata Pharmaceuticals (ARMP)
ICCM logo
IceCure Medical Ltd (ICCM)
HYPR logo
Hyperfine (HYPR)
TARA logo
Protara Therapeutics (TARA)
Citius Oncology (CTOR)
ABOS logo
Acumen Pharmaceuticals (ABOS)

FAQ

  • What is the ticker symbol for VistaGen Therapeutics?
  • Does VistaGen Therapeutics pay dividends?
  • What sector is VistaGen Therapeutics in?
  • What industry is VistaGen Therapeutics in?
  • What country is VistaGen Therapeutics based in?
  • When did VistaGen Therapeutics go public?
  • Is VistaGen Therapeutics in the S&P 500?
  • Is VistaGen Therapeutics in the NASDAQ 100?
  • Is VistaGen Therapeutics in the Dow Jones?
  • When was VistaGen Therapeutics's last earnings report?
  • When does VistaGen Therapeutics report earnings?
  • Should I buy VistaGen Therapeutics stock now?

What is the ticker symbol for VistaGen Therapeutics?

The ticker symbol for VistaGen Therapeutics is NASDAQ:VTGN

Does VistaGen Therapeutics pay dividends?

No, VistaGen Therapeutics does not pay dividends

What sector is VistaGen Therapeutics in?

VistaGen Therapeutics is in the Healthcare sector

What industry is VistaGen Therapeutics in?

VistaGen Therapeutics is in the Biotechnology industry

What country is VistaGen Therapeutics based in?

VistaGen Therapeutics is headquartered in United States

When did VistaGen Therapeutics go public?

VistaGen Therapeutics's initial public offering (IPO) was on June 21, 2011

Is VistaGen Therapeutics in the S&P 500?

No, VistaGen Therapeutics is not included in the S&P 500 index

Is VistaGen Therapeutics in the NASDAQ 100?

No, VistaGen Therapeutics is not included in the NASDAQ 100 index

Is VistaGen Therapeutics in the Dow Jones?

No, VistaGen Therapeutics is not included in the Dow Jones index

When was VistaGen Therapeutics's last earnings report?

VistaGen Therapeutics's most recent earnings report was on Feb 13, 2025

When does VistaGen Therapeutics report earnings?

The next expected earnings date for VistaGen Therapeutics is Jun 11, 2025

Should I buy VistaGen Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions